Given the frequent amplification of PTDSS1 in patients with cancer and the negative correlation between PTDSS1 level and response to ICT in some cancer types, our data suggest that combining PTDSS1 inhibition with ICT could serve as a promising therapeutic strategy for cancer treatment across tumor types. Here, PTDSS1 is linked to neoplasm.